{"id":7401,"date":"2017-05-24T10:42:33","date_gmt":"2017-05-24T15:42:33","guid":{"rendered":"https:\/\/fomatmedical.com\/?p=7401"},"modified":"2026-04-23T14:37:54","modified_gmt":"2026-04-23T21:37:54","slug":"minority-participation-clinical-trials","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/minority-participation-clinical-trials\/","title":{"rendered":"Diversidad en los ensayos cl\u00ednicos: se necesitan m\u00e1s minor\u00edas para que la investigaci\u00f3n sea relevante para todos"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

Minority Participation in Clinical Trials: Why It Matters and What Stands in the Way<\/h3>\n

Minority participation in clinical trials remains critically low. According to the National Institutes of Health National Institute on Minority Health and Health Disparities, minorities account for fewer than 10 percent of patients enrolled in clinical trials. This gap has profound consequences for the relevance and applicability of research findings across diverse populations.<\/p>\n

“The most important reason we need more minorities in clinical trials is to ensure that the discoveries, the treatments, interventions, and prevention strategies are going to be relevant to those populations,” said Consuelo Hopkins Wilkins, MD, of the Meharry Vanderbilt Alliance. “Much of the work that has been done cannot be applied to minorities because they are not represented in the data.”<\/p>\n

Why Minority Participation in Clinical Trials Is So Low<\/h4>\n

Luz Claudio, PhD, professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai, co authored a study assessing the impact of socioeconomic factors on clinical trial participation among parents of New York City school children. Her findings highlighted a critical insight: minorities would participate in medical research if asked by a trusted physician, particularly one who shares their cultural background.<\/p>\n

“Our conclusion was that minorities would participate in medical research if asked by their trusted physician, particularly if that physician is also a minority,” Claudio said.<\/p>\n

Trust is consistently identified as the most significant barrier to minority participation in clinical trials. Historical research abuses, including the Tuskegee Syphilis Study, have created lasting skepticism toward medical institutions among many communities. Wilkins noted that trust can be strengthened through culturally congruent research teams, transparent communication, and community vetting of researchers.<\/p>\n

“We do know that for some groups, having someone who is culturally congruent on the team makes them more trusting, for example, having a Latino trial coordinator or principal investigator when working with that group,” she said.<\/p>\n

Beyond trust, practical logistics create additional barriers. Long distance travel to trial sites, time commitments, child care costs, and concerns about insurance coverage and out of pocket expenses all reduce willingness to enroll. Andrea Denicoff, RN, MS, head of clinical trials operations for the NCI’s National Clinical Trials Network, noted that logistical barriers are frequently underestimated. “If participating in a clinical trial requires a long-term commitment or traveling long distances, it limits your chances of recruiting patients. For some potential enrollees, child care is an issue. They can’t afford it.”<\/p>\n

Barriers Are Not Limited to Minorities<\/h4>\n

Minority participation in clinical trials is not the only challenge facing clinical research enrollment. Only 4 in 10 Americans overall hold a positive impression of clinical trials, and only about one third say they would be likely to enroll in one, according to a survey commissioned by Memorial Sloan Kettering Cancer Center.<\/p>\n

Paul Sabbatini, MD, deputy physician in chief for clinical research at MSK, found the results concerning. “Nearly every advance in cancer today was first evaluated in a clinical trial. Clinical trials offer our best thinking toward finding better ways to prevent, treat, and cure cancer.” His team found that after patients read a brief written explanation of the importance of clinical trials, positive impressions rose to 60 percent and likelihood to enroll increased to 44 percent. Education, in other words, moves the needle significantly.<\/p>\n

Strategies to Increase Minority Participation in Clinical Trials<\/h4>\n

Researchers and institutions have identified several approaches that meaningfully improve minority participation in clinical trials. Patient navigators have emerged as one of the most effective tools. A study published in the Journal of Oncology Practice found that participants assisted by patient navigators were twice as likely to remain in trials, and enrollment nearly doubled over the course of the project. Navigators communicate with potential participants by phone, meet with them before clinical appointments, and help them understand and complete consent processes.<\/p>\n

Community outreach that goes beyond traditional advertising has also proven effective. Denicoff emphasized that posting flyers or placing newspaper ads is not sufficient. “For minorities and underserved communities, churches, barbershops, hair salons, and other types of community outreach are a good way to spread information, but that is not enough. People still have to find and enroll in a trial.”<\/p>\n

William J. Roberts, JD, health law counsel to Yale New Haven Hospital, recommended that academic medical centers collaborate with federally qualified health centers serving minority populations and establish training programs for minority physicians on how to advocate for clinical trial participation among their patients.<\/p>\n

The FDA declared 2016 the Year of Diversity in Clinical Trials and introduced demographic profile snapshots for approved drugs. The National Cancer Institute Community Oncology Research Program actively recruits minorities to participate in trials within their own communities. These initiatives reflect growing institutional recognition that the problem requires structural solutions, not just individual outreach.<\/p>\n

FOMAT’s Commitment to Inclusive Research<\/h4>\n

Increasing minority participation in clinical trials is central to FOMAT’s mission. Our investigator network is built in communities that have historically been underrepresented in clinical research, and our patient recruitment approach prioritizes cultural relevance, community engagement, and the removal of logistical barriers to participation. We believe that diverse enrollment is not a compliance exercise but a scientific imperative.<\/p>\n

To learn more about our diversity capabilities<\/a> or explore our active studies<\/a>, visit fomatmedical.com. For the original source of this article, visit AAMC News<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n
<\/div>\n
<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

La participaci\u00f3n de las minor\u00edas en los ensayos cl\u00ednicos: por qu\u00e9 es importante y qu\u00e9 obst\u00e1culos se interponen La participaci\u00f3n de las minor\u00edas en los ensayos cl\u00ednicos sigue siendo extremadamente baja. Seg\u00fan el Instituto Nacional de Salud y el Instituto Nacional de Salud de las Minor\u00edas y Disparidades en la Salud, las minor\u00edas representan menos de\u2026<\/p>","protected":false},"author":3,"featured_media":87451,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[968],"tags":[918,1115,1183,1116,1185,914,906],"class_list":["post-7401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-clinical-research","tag-clinical-research-diversity","tag-clinical-trial","tag-clinical-trials-diversity","tag-diversity","tag-research","tag-trials"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/7401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=7401"}],"version-history":[{"count":0,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/7401\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/87451"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=7401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=7401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=7401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}